Yorktown Heights, Canada

Thomas Meagher

This inventor holds 1 USPTO granted patent. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Meagher. Retrieved from https://idiyas.com/inventor/thomas-meagher-x3ip2yg2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Meagher: Innovator in T Cell Receptor Technology

Introduction

Thomas Meagher is a notable inventor based in Yorktown Heights, California. He has made significant contributions to the field of immunology, particularly in the development of T cell receptors. His work has implications for cancer treatment and other therapeutic areas.

Latest Patents

Thomas Meagher holds a patent for "NY-ESO-1 T Cell Receptors and Methods of Use Thereof." This patent represents a crucial advancement in the understanding and application of T cell receptors in medical science. He has 1 patent to his name, showcasing his innovative contributions to the field.

Career Highlights

Meagher is currently employed at Regeneron Pharmaceuticals, Inc., a leading biotechnology company known for its focus on developing medicines for serious diseases. His role at Regeneron allows him to work on cutting-edge research and development projects that aim to improve patient outcomes.

Collaborations

Throughout his career, Thomas has collaborated with several talented individuals, including Robert Babb and Johanna Hansen. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of their shared goals in the field of immunology.

Conclusion

Thomas Meagher is a distinguished inventor whose work in T cell receptor technology is paving the way for new therapeutic approaches. His contributions to Regeneron Pharmaceuticals and the scientific community are noteworthy and impactful.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…